A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

What this study is about

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

Who can join (things the study team will check)

✅ You may be able to join if…

• Body weight within 40-110 kilograms (kg) (88-242 pounds [lbs]) and a body mass index within the range 18-34 kg/m2
• Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria
• Has received monotherapy treatment
• An MDS-UPDRS Part IV score of 0 at screening and prior to randomization
• Hoehn and Yahr (H\&Y) Stage 1 or 2 off medication at screening and prior to randomization
• Agreement to adhere to the contraception requirements

🚫 You may not be able to join if…

• Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
• Medical history indicating a parkinsonian syndrome other than idiopathic PD
• Diagnosis of a significant neurologic disease other than PD
• Chronic uncontrolled hypertension

Where this trial is running

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• Barrow Neurological Institute, Phoenix, Arizona, United States
• Neurology Center of North Orange County, Fullerton, California, United States
• UC San Diego, La Jolla, California, United States
• Keck School of Medicine of USC, Los Angeles, California, United States
• UCLA Neurology Outpatient Clinic, Los Angeles, California, United States
• Parkinson?s Research Centers of America ? Palo Alto, Palo Alto, California, United States
• Profound Research LLC at The Neurology Center of Southern California, Pasadena, California, United States
• UCSF Weill Institute for Neurosciences, San Francisco, California, United States
• Rocky Mountain Movement Disorders, Englewood, Colorado, United States
• Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States
• Georgetown University, Washington D.C., District of Columbia, United States

+ 162 more sites.

Who to contact

Reference Study ID Number: BN44715 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07174310.